Human Angiopoietin-2 / ANGPT2 Protein, His Tag
分子別名(Synonym)
ANGPT2,AGPT2,ANG2,Angiopoietin-2
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human Angiopoietin-2, His Tag (AN2-H52H4) is expressed from human 293 cells (HEK293). It contains AA Tyr 19 - Phe 496 (Accession # O15123-1).
Predicted N-terminus: Tyr 19
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 56.8 kDa. The protein migrates as 65-80 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in 20 mM MOPS, 150 mM NaCl, 5 mM CHAPS, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
血管生成素-2也稱為ANGPT2、AGPT2、ANG2,是一種分泌型糖蛋白,在血管生成和炎癥中起著復(fù)雜的作用。Ang2在發(fā)育過程中廣泛表達(dá),但在出生后僅限于胎盤、卵巢和子宮等高度血管生成組織。它在血管內(nèi)皮細(xì)胞(EC)中含量特別豐富,儲存在細(xì)胞內(nèi)Weibel-Palade體內(nèi)。Ang2和相關(guān)的血管生成素1(Ang1)都是受體酪氨酸激酶Tie 2的配體。Ang2作為促血管生成因子發(fā)揮作用,盡管它也可以誘導(dǎo)EC死亡和血管退化。從靜止的EC釋放后,它通過促進EC的存活、增殖和遷移以及破壞EC與血管周圍細(xì)胞之間的相互作用來調(diào)節(jié)血管重塑。Ang2是出生后血管重塑所必需的,它在淋巴管發(fā)育過程中與Ang1協(xié)同作用。它介導(dǎo)EC上ICAM1和VCAM-1的上調(diào),這有助于炎癥期間白細(xì)胞的粘附。Ang2競爭性抑制Tie2介導(dǎo)的Ang1誘導(dǎo)的內(nèi)皮細(xì)胞反應(yīng),并降低血管完整性。但是Ang2的作用是有爭議的,因為其他研究報告了相反的結(jié)果。Ang2的過表達(dá)破壞血管重塑,誘導(dǎo)內(nèi)皮細(xì)胞凋亡,可能在腫瘤血管生成中起重要調(diào)節(jié)作用。Ang2還促進腦室下區(qū)祖細(xì)胞的神經(jīng)元分化和遷移。
關(guān)鍵字: Angiopoietin-2;ANGPT2蛋白;ANGPT2重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。